Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison

Table 4 Costs of therapy over a 5-year time horizon

Cost particulars	OLAI (€)		RLAI (€)
	Mean	SD	Mean	SD
Drug cost^a	16152.18	71.50	16676.88	82.52
Administration cost	1949.85	13.21	2430.71	21.77
Cost per relapse/hospitalisation^b	6860.26	169.61	8955.42	173.35
Other costs^c	9047.91	41.76	8886.87	44.14
Total cost per patient	34010.21	207.83	36949.88	251.45

(The Mean and Std Dev are outcomes of the model run over 5 years with 100 replications).
^aDrug cost includes cost of study drug and concomitant medications.
^bSince the study assumed hospitalisation as proxy for relapse.
^cOther costs include specialist visits and other medical costs (i.e. routine management, treatment of adverse events and cost of switching).
SD = Standard deviation.

ISSN: 1471-244X